| Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Aplastic Anemia |
| A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Hematopoietic Cell Transplantation With Cryopreserved Grafts for Severe Aplastic Anemia |
|
Biology of blood and marrow transplantation: journal of the America Society of Blood and Marrow Transplantation |
Aplastic Anemia |
| Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. |
|
Biol Blood Marrow Transplant. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia |
|
Biol Blood Marrow Transplant |
Aplastic Anemia |
| The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome |
|
BioDrugs |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Hematopoiesis and therapy related MDS/AML |
|
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
